DEC 12, 2015 7:01 AM PST

FDA Green Lights Device To Save Hair During Chemo

WRITTEN BY: Xuan Pham
For the first time in the US, there will be an alternative to hair loss for patients undergoing chemotherapy. The Food and Drug Administration recently approved for the US market a scalp-cooling cap that reduces hair loss related to breast cancer treatment.
 
Cooling cap allows patients to keep hair during chemotherapy

Traditional cancer treatment with chemotherapy involves using highly toxic drugs to kill errant cancer cells. Because the majority of these drugs do not discriminate between cancer and normal cells, patients experience collateral damages as adverse side effects. Hair loss (alopecia) is a common side effect of certain types of chemotherapy, typically associated with treatment for breast cancer. Though considered a temporary effect, minimizing hair loss is important to the quality of life for many patients.

"Some of today's most powerful, life-saving chemotherapy treatments still cause complete hair loss, a side effect that many women consider to be emotionally devastating," said Dr. Hope Rugo, Principal Investigator for the study and Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center.

Named DigniCap, the cooling system is manufactured by Dignitana in Sweden. It works by circulating a liquid coolant to a tight-fitting silicone cap worn on the head during chemotherapy sessions. A second cap made of neoprene covers this cooling cap to act as insulation and prevent loss of cooling. The entire system is computerized with sensors that continuously monitor scalp temperature and allow the system to maintain optimal cooling throughout treatment.

The coldness of the cap acts to constrict blood vessels in the scalp, reducing blood flow to the hair follicles and protecting the hair from the flow of toxic chemotherapy agents in the body. In addition, the cooling action slows down cell division activities of the hair follicles, which makes them less susceptible to the uptake of chemotherapy drugs. These factors together reduce the risk of hair loss associated with cancer treatment.

A U.S. clinical trial studied the effects of the DigniCap in 122 women with Stage I and Stage II breast cancer who were undergoing chemotherapy. Patients then self-assessed the hair loss using standardized photographs at one month after the last chemotherapy cycle. More than 66% of these patients reported keeping at least 50% of their hair. In addition, patients reported high satisfaction for the experience: a mean of 87.5 satisfaction with the decision to use the DigniCap, a mean of 70.9 for hair quantity, and a mean of 69.1 for hair quality (ranked from 0 to 100, with 100 being “completely satisfied”). No severe adverse events were reported.

The US trial only evaluated the device on chemotherapy regimens using taxanes, such as paclitaxel and docetaxel. However, abroad the device has also been studied with anthracyclines, such as epirubicin and doxorubicin.

While the risk of the chemotherapy drug missing breast cancer cells in the scalp is considered extremely low, the benefits of the cooling cap are significant. The device minimizes the psychological impact of the diagnosis and makes the chemotherapy process more tolerable. Reducing hair loss during chemotherapy allows these patients to retain some normalcy and privacy in their lives. Thus many people are pleased with the FDA's clearance of this device into US markets.
 

Source: Fierce Medical Device release
 
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 23, 2020
Clinical & Molecular DX
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
OCT 23, 2020
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
Cardiovascular disease is the leading cause of death globally, resulting in the loss of nearly 18 million lives each yea ...
OCT 28, 2020
Cancer
Protecting the Head and Neck from Off Target Radiation
OCT 28, 2020
Protecting the Head and Neck from Off Target Radiation
Radiotherapy alone or with chemotherapy is the go-to treatment for head and neck cancers. Unfortunately, head and neck t ...
NOV 18, 2020
Clinical & Molecular DX
Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease
NOV 18, 2020
Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease
Researchers have identified a new prognostic biomarker for Guillain-Barré syndrome (GBS), a rare autoimmune disor ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
FEB 04, 2021
Clinical & Molecular DX
Neurological and Psychiatric Aftershocks of the Pandemic
FEB 04, 2021
Neurological and Psychiatric Aftershocks of the Pandemic
One in eight COVID-19 survivors have received a diagnosis of a neurological or psychiatric condition in the year followi ...
MAR 02, 2021
Cardiology
Creating a Light Switch in the Heart to Regulate Heart Rate
MAR 02, 2021
Creating a Light Switch in the Heart to Regulate Heart Rate
Often when it is dark, we go for a flashlight or our phone to see where we are going. What if I told you that is much th ...
Loading Comments...